This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Porfiromycin
DrugBank Accession Number
DB06478
Background

Porfiromycin is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 348.359
Monoisotopic: 348.14336976
Chemical Formula
C16H20N4O5
Synonyms
  • Porfiromycin
External IDs
  • NSC-56410
  • U-14,743
  • U-14743

Pharmacology

Indication

Investigated for use/treatment in head and neck cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ArticaineThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Cinchocaine.
CocaineThe risk or severity of methemoglobinemia can be increased when Porfiromycin is combined with Cocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Promycin

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as mitomycins. These are polycyclic compounds with a structure based on an aziridine ring linked to a 7-amino-6-methyl-cyclohexa[b]pyrrolizine-5,8-dione.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolequinones
Direct Parent
Mitomycins
Alternative Parents
Indoles / Quinones / Pyrrolizines / N-methylpiperazines / Vinylogous amides / Carbamate esters / Pyrrolines / Pyrrolidines / Trialkylamines / Organic carbonic acids and derivatives
show 7 more
Substituents
1,4-diazinane / Aliphatic heteropolycyclic compound / Amine / Azacycle / Aziridine / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Enamine / Hydrocarbon derivative
show 21 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
H1WK901OA6
CAS number
801-52-5
InChI Key
HRHKSTOGXBBQCB-VFWICMBZSA-N
InChI
InChI=1S/C16H20N4O5/c1-6-10(17)13(22)9-7(5-25-15(18)23)16(24-3)14-8(19(14)2)4-20(16)11(9)12(6)21/h7-8,14H,4-5,17H2,1-3H3,(H2,18,23)/t7-,8+,14+,16-,19?/m1/s1
IUPAC Name
[(4S,6S,7R,8S)-11-amino-7-methoxy-5,12-dimethyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.0^{2,7}.0^{4,6}]trideca-1(9),11-dien-8-yl]methyl carbamate
SMILES
CO[C@]12[C@@H]3[C@H](CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O)N3C

References

General References
Not Available
ChemSpider
12565
ChEMBL
CHEMBL521078
ZINC
ZINC000100091597

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCarcinoma of Unknown Primary / Head and Neck Carcinoma1
3CompletedTreatmentHead and Neck Carcinoma1
3TerminatedTreatmentNeoplasms, Head and Neck1
1TerminatedTreatmentNeoplasms, Head and Neck1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility23.3 mg/mLALOGPS
logP0ALOGPS
logP-2.5Chemaxon
logS-1.2ALOGPS
pKa (Strongest Acidic)0.9Chemaxon
pKa (Strongest Basic)4.15Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area127.96 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity88.56 m3·mol-1Chemaxon
Polarizability34.81 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xanthine oxidase activity
Specific Function
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Ha...
Gene Name
XDH
Uniprot ID
P47989
Uniprot Name
Xanthine dehydrogenase/oxidase
Molecular Weight
146422.99 Da
References
  1. Pan SS, Iracki T: Metabolites and DNA adduct formation from flavoenzyme-activated porfiromycin. Mol Pharmacol. 1988 Aug;34(2):223-8. [Article]

Drug created at March 19, 2008 16:34 / Updated at February 21, 2021 18:52